Veraxa Biotech stock analysis
Austin, Texas, United States, October 21st, 2026, FinanceWire VERAXA is implementing FDA-aligned New Approach Methodologies (“NAMs”) across its preclinical research programs, aiming to improve the relevance of experimental findings to
Austin, Texas, United States, October 13th, 2026, FinanceWire VERAXA Biotech (NASDAQ:VRXA), an emerging leader in designing novel cancer therapies, presented its first in vivo proof-of-concept data and additional in vitro
Austin, Texas, United States, October 7th, 2026, FinanceWire VERAXA Biotech (NASDAQ:VRXA), a developer of next-generation antibody-based cancer therapies, provided an update on its strategy to implement U.S. Food and Drug
Austin, Texas, United States, September 24th, 2026, FinanceWire VERAXA Biotech (NASDAQ:VRXA) is shifting its focus to advancing its oncology pipeline and implementing industrial partnerships for its technology platforms and products
Austin, Texas, United States, September 22nd, 2026, FinanceWire VERAXA is advancing an oncology pipeline centered on its proprietary BiTAC(R) platform, alongside additional antibody-drug conjugate and engineered-antibody technologies. The company entered
Austin, Texas, United States, September 18th, 2026, FinanceWire VERAXA has appointed Raju Willener as Chief Financial Officer, effective immediately. Willener brings more than 30 years of international experience spanning investment
Austin, Texas, United States, September 16th, 2026, FinanceWire VERAXA is developing antibody-based cancer therapies aimed at improving the therapeutic window of existing treatment modalities. Its proprietary BiTAC platform uses two
Austin, Texas, United States, September 8th, 2026, FinanceWire VERAXA Biotech (NASDAQ:VRXA) a developer of next-generation antibody-based cancer therapies, announced the appointment of Raju Willener as chief financial officer, effective immediately. Willener
Austin, Texas, United States, August 28th, 2026, FinanceWire VERAXA Biotech and Secarna Pharmaceuticals have reported an initial in vitro proof of concept for an antibody oligonucleotide conjugate (“AOC”) developed through
Austin, Texas, United States, August 25th, 2026, FinanceWire Following completion of the initial phase of its collaboration with OmniAb, VERAXA will engineer the final VXA-222 candidate and conduct the preclinical
Veraxa Biotech (VRXA) and Secarna Pharmaceuticals announced initial results from their strategic research collaboration to develop next-generation antibody oligonucleotide conjugates for the treatment of autoimmune and chronic immune diseases. In
Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company was founded in 2021 and is based in Heidelberg, Germany.
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 5 | 7 |
| Technical Analysis | 3 | 5 | 1 |
| Moving Averages | 6 | 0 | 6 |
